Capricor Therapeutics Inc Financials
This page shows Capricor Therapeutics Inc (CAPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Capricor Therapeutics Inc has an operating margin of -191.1%, meaning the company retains $-191 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -95.6% the prior year.
Capricor Therapeutics Inc's revenue declined 11.5% year-over-year, from $25.2M to $22.3M. This contraction results in a growth score of 0/100.
Capricor Therapeutics Inc carries a low D/E ratio of 0.17, meaning only $0.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.77, Capricor Therapeutics Inc holds $7.77 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Capricor Therapeutics Inc generated -$40.0M in operating cash flow, capex of $1.2M consumed most of it, leaving -$41.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Capricor Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Capricor Therapeutics Inc generates $0.99 in operating cash flow (-$40.0M OCF vs -$40.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Capricor Therapeutics Inc generated $22.3M in revenue in fiscal year 2024. This represents a decrease of 11.5% from the prior year.
Capricor Therapeutics Inc's EBITDA was -$41.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 78.8% from the prior year.
Capricor Therapeutics Inc generated -$41.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 53.0% from the prior year.
Capricor Therapeutics Inc reported -$40.5M in net income in fiscal year 2024. This represents a decrease of 81.6% from the prior year.
Capricor Therapeutics Inc earned $-1.15 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 38.6% from the prior year.
Capricor Therapeutics Inc held $11.3M in cash against $0 in long-term debt as of fiscal year 2024.
Capricor Therapeutics Inc had 46M shares outstanding in fiscal year 2024. This represents an increase of 46.3% from the prior year.
Capricor Therapeutics Inc's operating margin was -191.1% in fiscal year 2024, reflecting core business profitability. This is down 95.5 percentage points from the prior year.
Capricor Therapeutics Inc's net profit margin was -181.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 93.2 percentage points from the prior year.
Capricor Therapeutics Inc invested $50.0M in research and development in fiscal year 2024. This represents an increase of 37.1% from the prior year.
Capricor Therapeutics Inc invested $1.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 11.0% from the prior year.
CAPR Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M+24.9% | $1.0M0.0% | $1.0M-90.6% | $11.1M+392.1% | $2.3M-43.1% | $4.0M-19.1% | $4.9M-59.4% | $12.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $20.4M-7.7% | $22.0M+16.6% | $18.9M+30.0% | $14.6M+23.3% | $11.8M-5.6% | $12.5M+12.6% | $11.1M+11.7% | $9.9M |
| SG&A Expenses | $5.9M+4.5% | $5.7M-6.5% | $6.1M+42.0% | $4.3M+23.4% | $3.5M+13.3% | $3.1M-24.9% | $4.1M+18.7% | $3.4M |
| Operating Income | -$26.3M+5.2% | -$27.7M-11.0% | -$25.0M-224.5% | -$7.7M+40.8% | -$13.0M-12.2% | -$11.6M-12.9% | -$10.3M-701.2% | -$1.3M |
| Interest Expense | $60K+9.8% | $55K+116.0% | $25K+1.9% | $25K+6.4% | $23K+276.0% | $6K+67.4% | $4K-95.4% | $80K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$24.6M+5.2% | -$25.9M-6.2% | -$24.4M-242.7% | -$7.1M+43.3% | -$12.6M-14.2% | -$11.0M-12.3% | -$9.8M-1185.2% | -$762K |
| EPS (Diluted) | $-0.54+5.3% | $-0.57-7.5% | $-0.53-381.8% | $-0.11+71.1% | $-0.38-8.6% | $-0.35-12.9% | $-0.31-1650.0% | $0.02 |
CAPR Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $126.4M-5.3% | $133.6M-13.1% | $153.8M-9.8% | $170.5M+83.4% | $93.0M+142.8% | $38.3M-22.6% | $49.4M-15.8% | $58.7M |
| Current Assets | $101.0M-18.7% | $124.1M-15.1% | $146.3M-10.5% | $163.4M+90.4% | $85.8M+179.8% | $30.7M-25.9% | $41.4M-18.6% | $50.9M |
| Cash & Equivalents | $19.5M-16.1% | $23.2M-19.3% | $28.8M+155.1% | $11.3M-83.5% | $68.4M+539.7% | $10.7M+72.0% | $6.2M-57.7% | $14.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | $1.9M | N/A | N/A | N/A | N/A |
| Total Liabilities | $42.6M+48.9% | $28.6M+9.5% | $26.1M+4.4% | $25.0M+1.3% | $24.7M-7.8% | $26.8M-13.7% | $31.0M-14.2% | $36.1M |
| Current Liabilities | $28.1M-0.9% | $28.4M+27.1% | $22.3M+6.2% | $21.0M+2.7% | $20.5M-8.4% | $22.4M-15.3% | $26.4M-15.6% | $31.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $83.9M-20.1% | $105.0M-17.8% | $127.6M-12.2% | $145.5M+113.1% | $68.3M+493.5% | $11.5M-37.6% | $18.4M-18.4% | $22.6M |
| Retained Earnings | -$274.7M-9.8% | -$250.1M-11.6% | -$224.2M-12.2% | -$199.8M-3.7% | -$192.7M-7.0% | -$180.2M-6.5% | -$169.2M-6.1% | -$159.4M |
CAPR Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.7M+2.2% | -$20.1M-212.8% | -$6.4M+56.5% | -$14.8M-27.1% | -$11.6M+5.3% | -$12.3M-868.8% | -$1.3M+89.1% | -$11.6M |
| Capital Expenditures | $56K-80.6% | $288K-67.9% | $896K+83.3% | $489K+5245.0% | $9K-84.8% | $60K-90.1% | $609K+8.9% | $559K |
| Free Cash Flow | -$19.7M+3.3% | -$20.4M-178.5% | -$7.3M+52.0% | -$15.3M-31.2% | -$11.7M+5.6% | -$12.3M-557.9% | -$1.9M+84.6% | -$12.2M |
| Investing Cash Flow | $16.0M+9.6% | $14.5M-39.1% | $23.9M+119.4% | -$123.4M-6254.8% | $2.0M-86.4% | $14.7M+254.7% | -$9.5M-62.1% | -$5.9M |
| Financing Cash Flow | $7K-64.5% | $20K-61.1% | $50K-99.9% | $81.1M+20.4% | $67.3M+3157.1% | $2.1M-9.7% | $2.3M-90.1% | $23.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | $0 | $0 | N/A | N/A | N/A |
CAPR Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -114.1%+28.0pp | -142.1%-28.3pp | -113.8%-44.6pp | -69.2%+506.1pp | -575.2%-283.4pp | -291.9%-82.7pp | -209.2%-198.6pp | -10.6% |
| Net Margin | -118.6%+28.6pp | -147.3%-31.0pp | -116.2%-52.3pp | -63.9%+491.3pp | -555.2%-278.2pp | -277.0%-77.4pp | -199.6%-193.3pp | -6.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 109.6% |
| Return on Assets | -19.4%-0.0pp | -19.4%-3.5pp | -15.9%-11.7pp | -4.2%+9.3pp | -13.5%+15.2pp | -28.7%-8.9pp | -19.8%-18.5pp | -1.3% |
| Current Ratio | 3.59-0.8 | 4.37-2.2 | 6.55-1.2 | 7.77+3.6 | 4.19+2.8 | 1.37-0.2 | 1.57-0.1 | 1.63 |
| Debt-to-Equity | 0.51+0.2 | 0.27+0.1 | 0.20+0.0 | 0.17-0.2 | 0.36-2.0 | 2.33+0.6 | 1.68+0.1 | 1.60 |
| FCF Margin | -173.0%+406.8pp | -579.8%-1659.8pp | 1080.0%+1217.3pp | -137.3%+377.8pp | -515.2%-204.2pp | -310.9%-272.7pp | -38.3%+62.3pp | -100.5% |
Similar Companies
Frequently Asked Questions
What is Capricor Therapeutics Inc's annual revenue?
Capricor Therapeutics Inc (CAPR) reported $22.3M in total revenue for fiscal year 2024. This represents a -11.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Capricor Therapeutics Inc's revenue growing?
Capricor Therapeutics Inc (CAPR) revenue declined by 11.5% year-over-year, from $25.2M to $22.3M in fiscal year 2024.
Is Capricor Therapeutics Inc profitable?
No, Capricor Therapeutics Inc (CAPR) reported a net income of -$40.5M in fiscal year 2024, with a net profit margin of -181.7%.
What is Capricor Therapeutics Inc's earnings per share (EPS)?
Capricor Therapeutics Inc (CAPR) reported diluted earnings per share of $-1.15 for fiscal year 2024. This represents a -38.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Capricor Therapeutics Inc's EBITDA?
Capricor Therapeutics Inc (CAPR) had EBITDA of -$41.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Capricor Therapeutics Inc's operating margin?
Capricor Therapeutics Inc (CAPR) had an operating margin of -191.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Capricor Therapeutics Inc's net profit margin?
Capricor Therapeutics Inc (CAPR) had a net profit margin of -181.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Capricor Therapeutics Inc's free cash flow?
Capricor Therapeutics Inc (CAPR) generated -$41.2M in free cash flow during fiscal year 2024. This represents a -53.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Capricor Therapeutics Inc's operating cash flow?
Capricor Therapeutics Inc (CAPR) generated -$40.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Capricor Therapeutics Inc's total assets?
Capricor Therapeutics Inc (CAPR) had $170.5M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Capricor Therapeutics Inc's capital expenditures?
Capricor Therapeutics Inc (CAPR) invested $1.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Capricor Therapeutics Inc spend on research and development?
Capricor Therapeutics Inc (CAPR) invested $50.0M in research and development during fiscal year 2024.
How many shares does Capricor Therapeutics Inc have outstanding?
Capricor Therapeutics Inc (CAPR) had 46M shares outstanding as of fiscal year 2024.
What is Capricor Therapeutics Inc's current ratio?
Capricor Therapeutics Inc (CAPR) had a current ratio of 7.77 as of fiscal year 2024, which is generally considered healthy.
What is Capricor Therapeutics Inc's debt-to-equity ratio?
Capricor Therapeutics Inc (CAPR) had a debt-to-equity ratio of 0.17 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Capricor Therapeutics Inc's return on assets (ROA)?
Capricor Therapeutics Inc (CAPR) had a return on assets of -23.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Capricor Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Capricor Therapeutics Inc (CAPR) had $11.3M in cash against an annual operating cash burn of $40.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Capricor Therapeutics Inc's Piotroski F-Score?
Capricor Therapeutics Inc (CAPR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Capricor Therapeutics Inc's earnings high quality?
Capricor Therapeutics Inc (CAPR) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Capricor Therapeutics Inc?
Capricor Therapeutics Inc (CAPR) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.